Manogepix demonstrates potent in vitro activity against Aspergillus, Coccidioides, Scopulariopsis/Microascus, Rasamsonia, and Purpureocillium species, including strains with in vitro resistance to other antifungals. (PubMed, Antimicrob Agents Chemother) - Jun 5, 2026 - "Manogepix, the active moiety of the prodrug fosmanogepix, is a novel investigational agent in clinical trials that inhibits Gwt1, depleting glycosylphosphatidylinositol (GPI)-anchored mannoproteins critical for fungal cell wall integrity...Minimum effective concentrations (MECs) (manogepix and caspofungin) and minimum inhibitory concentrations (MICs) (amphotericin B, fluconazole, isavuconazole, itraconazole, posaconazole, and fluconazole) were determined by CLSI M38 broth dilution...Reduced or variable activity for manogepix was observed against Curvularia, Exophiala, and Exserohilum rostratum. Additional studies are warranted to determine if this potent in vitro activity translates into in vivo activity and enhanced clinical efficacy against infections caused by these fungal pathogens."
Journal • Preclinical • Infectious Disease
|
|
Carmita Sanders; Connie Cañete-Gibas; Hoja P Patterson; Nathan P Wiederhold
|